Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

cholera - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

cholera

MONDO:0015766

Also known as:Vibrio choleraeVibrio cholerae caused disease or disorderVibrio cholerae disease or disorder

Find Clinical TrialsTrials

Overview

Cholera is an infectious disease, caused by intestinal infection with Vibrio cholerae, characterized by massive watery diarrhea and severe dehydration that can lead to shock and death if left untreated.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials14 registered · 11 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Diarrhea; and common findings: Muscle weakness, Tachycardia, Acidosis, and Dehydration and others. 33 total HPO annotations.

Organ System	Phenotype Count	Example Features
Digestive system	4	Diarrhea, Vomiting, Abdominal pain

Diagnosis

Biomarker and diagnostic research for cholera has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for cholera. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for cholera, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for cholera. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Phenotype severity distribution: 1 very common feature, 13 common features.

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

14 clinical trials registered, 11 recruiting. Interventions under study include other interventions, biologic therapy, and drug therapy. Pipeline includes 2 PHASE4, 1 PHASE3, 3 PHASE2. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05166850](https://clinicaltrials.gov/study/NCT05166850)

Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:10 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:173

GARD

Genetic and Rare Diseases Info Center

GARD:6043

Questions for Your Care Team

→Are any of the 14 active clinical trials a good fit for my situation?
→What is the current development status of (+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Disease patterns and progression	99	44%
Research summaries	53	24%
Laboratory research	45	20%
Clinical study results	8	4%
New treatment approaches	8	4%
Other research	4	2%
Testing and diagnosis research	4	2%
Patient case studies	2	1%

Kisho

cholera

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

Cholera and Other <em>Vibrio </em>Illness Surveillance

CDC finalizes vaccine recommendation for adults traveling to areas with cholera - Media Statement

CDC Recommends Precautions during Holiday Travel to Haiti

cholera

Overview

Clinical Presentation

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Clinical Trials

Recent Publications

Latest News & Developments

Cholera and Other <em>Vibrio </em>Illness Surveillance

CDC finalizes vaccine recommendation for adults traveling to areas with cholera - Media Statement

CDC Recommends Precautions during Holiday Travel to Haiti